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Transcriptional activation of diverse cellular genes by the X protein (HBx) of hepatitis B virus (HBV) has
been suggested as one of the mechanisms for HBV-associated hepatocellular carcinoma. However, such
functions of HBx have been studied using transformed cells in culture and have not been examined in the
normal adult hepatocytes, a natural host of HBV. Using an efficient hepatocyte-specific virus-based gene
delivery system developed in our laboratory earlier, we studied the HBx action in vivo. We demonstrate that
following virosome-mediated delivery of HBx DNA, a large population (>50%) of hepatocytes express the HBx
protein in a dose-dependent manner, which induces a significant increase in the activity of extracellular
signal-regulated kinases (ERKs) in the livers of HBx-transfected mice. Inhibition of HBx-induced ERK
activation following intravenous administration of PD98059, a mitogen-activated protein kinase kinase kinase
(MEK) inhibitor, confirmed the requirement for MEK in the activation of ERKs by HBx. Induction of ERK
activity by HBx was sustained for up to 30 days. Interestingly, sustained activation of c-Jun N-terminal kinases
(JNKs) for up to 30 days was also noted. Such constitutive ERK and JNK activation as a consequence of
continued HBx expression also led to sustained stimulation of further downstream events, such as increased
levels of c-Jun and c-Fos proteins along with the persistent induction of activator protein 1 binding activity.
Taken together, our data suggest a critical role of these molecules in HBx-mediated cell transformation.
Hepatitis B virus (HBV), a prototype member of mamma-
lian hepadnaviruses, predominantly infects host hepatocytes
and causes a spectrum of pathological processes, ranging from
inapparent infection to the later development of primary liver
cancer (61). The molecular mechanism underlying HBV-me-
diated carcinogenesis is incompletely understood. Nonethe-
less, it is postulated that it does not involve direct insertional
activation of proto-oncogenes, although modulation of cellular
gene expression by transmechanisms might play a significant
role (14, 19). The HBV-encoded X gene product (HBx) can
induce transformation of cultured cells and tumors in certain
transgenic mice, and the HBx gene is integrated in the host
chromosome in many tumors despite the absence of other
HBV genes (14, 39, 48). These observations shed light on the
mechanism of HBV-associated carcinogenesis and suggest the
relevance of the X open reading frame to the development of
hepatocellular carcinoma (HCC). Chromosomal DNA from
HBV-associated tumors often possesses X sequences, which, in
spite of being truncated, retain their transactivating function
and suggest the importance of HBx-mediated transactivation
in carcinogenesis (48). However, little is known about the exact
role of HBx in tumorigenesis. HBx deregulates cell cycle
checkpoints (10) and stimulates DNA synthesis, leading to the
proliferation of quiescent fibroblasts (33). Importantly, HBx
(16.5 kDa) is a moderate but broad-acting transcriptional
transactivator and activates a variety of cellular and viral genes,
including proto-oncogenes, such as c-myc, c-Fos, and c-Jun,
thus regulating in turn many host functions, such as transcrip-
tion, cell cycle progression, proliferation, apoptosis, and DNA
repair (2, 4, 32). However, HBx does not bind to DNA directly,
and transactivation involves direct protein-protein interactions
between HBx, the cellular transcription machinery, and other
regulatory proteins (48). HBx influences transcription directly
by interacting with the basal transcriptional apparatus and
bZip transcription factors (2). In the cytoplasm, which is its
predominant site of localization (18, 48), HBx activates tran-
scription indirectly by modulating signal transduction path-
ways, particularly protein kinase C (PKC) (27), JAK/STAT
(40), Src (30), and Ras signaling (9, 11, 36). Transcriptional
deregulation has thus been implicated as the possible mecha-
nism by which HBx mediates hepatocyte transformation.
Activation of the Ras-Raf-mitogen-activated protein kinase
(MAPK) cascade is necessary for cell growth and proliferation
(41, 55). MAPKs serve as convergence points in intracellular
signal transducing pathways and couple cytoplasmic signals to
the gene expression program (34). Constitutively active mu-
tants in this pathway exhibit enhanced kinase activity, leading
to the transformed phenotypes (15). The conditions that influ-
ence this pathway in the intact liver are emerging. Recent
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studies demonstrate the activation of MAPKs under both hor-
monal (e.g., epidermal growth factor and hepatocyte growth
factor) and nonhormonal (e.g., sodium orthovandate and par-
tial hepatectomy) stimulation of quiescent hepatocytes in the
intact liver (51, 59). Constitutive activation of the MAPK sig-
naling pathway has also been observed in a large number of
tumors (23, 24, 42, 57). Since many physiological and etiolog-
ical processes require extracellular signal-regulated kinase
(ERK) activation, it is intriguing to examine its role in the
HBx-induced signal transduction activity with a view to com-
prehend its possible relevance in carcinogenesis. Notably, all
the evidence provided on HBx-induced transactivation of cel-
lular signaling pathways has been obtained with transformed
cell lines in culture and reflects conditions that are nonnative
to the environment in which HBx is expressed during infection
with HBV. In addition, a number of studies have emphasized
the limited value of in vitro systems for the analysis of HBx
protein function and underscored the importance of in vivo
studies on HBx (54, 60). However, no evidence exists from
whole animals in support of HBx-induced modulation of signal
transduction pathways.
Exploiting the membrane-fusogenic ability of Sendai virus F
glycoprotein and the high affinity of the terminal -galactose-
containing ligand (present on F glycoprotein) for the asialo-
glycoprotein receptor on the hepatocyte surface, we have de-
veloped an efficient virus-based delivery system (F-virosomes)
(55a) to transfer foreign genes to mouse hepatocytes in vivo (6,
7, 53). Using this system, we have now introduced the HBx
gene into the whole animal and examined the effect of hepa-
tocyte-expressed HBx protein on signaling cascades. We dem-
onstrate for the first time that HBx expression in vivo induces
MAPKs and activator protein 1 (AP-1) activation persistently,
and we suggest that these changes precede carcinoma forma-
tion.
MATERIALS AND METHODS
Expression vector of HBx. The construction of a eukaryotic expression vector
for HBx has been described earlier (37). Briefly, the HBx gene was amplified as
a 481-bp DNA fragment by PCR using the full-length HBV template (adw
subtype) and the following oligonucleotide primers: forward, 5-CGGAATTCA
TGGCTGCTAGGCTGT-3, and reverse, 5-CGGAATTCTTAGGCAGAGG
TGAAAAAG-3. Finally, a 471-bp EcoRI fragment of the HBx gene was cloned
into pSG5 (Stratagene) under the control of the SV40 promoter. All plasmids
were isolated using the Qiagen Megaprep kit.
Intravenous injection of DNA-loaded virosomes, insulin, and PD98059 into
BALB/c mice. The F-virosomes containing HBx DNA were prepared following
our standardized protocol (53). In brief, 75 g of each plasmid was incubated
with a detergent-solubilized fraction of Sendai virus containing its envelope
devoid of hemagglutinin-neuraminidase protein. Finally, F-virosomes containing
the DNA were prepared by stepwise removal of detergent by using SM2
Biobeads (Bio-Rad). The membrane fusion-mediated cytosolic delivery of its
contents was evaluated by published protocols (6, 7) prior to their injection to
animals. Twelve-week-old female BALB/c mice (18 g) were injected intrave-
nously (i.v.) in the tail vein with 2 g of DNA loaded in F-virosomes. Twenty
micrograms of insulin (Sigma) in phosphate-buffered saline (PBS) was injected
i.v. into mice 1 h prior to sacrifice. i.v. administration of PBS containing 75 M
PD98059 (New England Biolabs) in 0.37% dimethyl sulfoxide was done 5 h
before the sacrifice of HBx- and insulin-injected mice. Injection of PBS alone
(mock injection), pSG5 vector DNA-loaded F virosomes, and PBS with 0.37%
dimethyl sulfoxide served as appropriate negative controls. Throughout the ex-
periments, these animals were maintained under constant room temperature
with a 12:12-h light-dark cycle under specific pathogen-free conditions and were
offered food and water ad libitum, and experiments were carried out in accor-
dance to Delhi University laws and regulations. At various time intervals, animals
were sacrificed and livers were processed as described below. A portion of each
liver was kept frozen for both the isolation of total RNA and the preparation of
nuclear extracts. All experiments were independently repeated at least three
times.
Histological and immunohistochemical methods. A portion of each liver from
injected mice was immediately fixed in Bouin’s fixative and dehydrated through
graded alcohol and xylene followed by embedding in paraffin wax. Paraffin-
embedded tissues were cut into 5-m sections, deparaffinized, and rehydrated.
For immunostaining, sections were washed in PBS for 10 min and blocked with
3% bovine serum albumin in PBS for an hour at 37°C. Subsequently, sections
were incubated with an HBx-specific monoclonal antibody (B-8/2/8) (37) for an
hour at 37°C. After three washes with PBS, sections were incubated with alkaline
phosphatase-conjugated goat anti-mouse immunoglobulin G (IgG) (Sigma) at
37°C for an hour. All antibody dilutions were made in 1.5% bovine serum
albumin in PBS. Following extensive washes with PBS, color development was
demonstrated with the addition of Fast Red solution (DAKO, Glostrup, Den-
mark). Finally, the slides were counterstained with Mayer’s hematoxylin, washed
in distilled water, and mounted in glycerol. The specificity of immunostaining was
verified by the use of PBS in place of primary antibody (data not shown). The
sections were examined using light microscopy and photographed (magnifica-
tion, 100).
Hepatocyte isolation from liver biopsy and HBx gene expression. Parenchymal
cell (hepatocytes) separation was carried out as described in an earlier report by
members of our group (53). To summarize, perfused livers were washed and
treated with 0.05% collagenase (GIBCO BRL). The resulting cell suspension was
filtered through a nylon mesh, and the filtrate was centrifuged to obtain a pellet
containing hepatocytes. Residual blood cells were separated from the hepatocyte
population by a modification of a method described earlier (43). Finally, hepa-
tocytes free of detectable red blood cells were collected.
(i) HBx protein detection in total hepatocyte lysates. After 2 days of injection
of HBx DNA-loaded F-virosomes, hepatocytes were isolated, directly lysed in
Laemmli sample buffer, and analyzed by sodium dodecyl sulfate–15% polyacryl-
amide gel electrophoresis (SDS–15% PAGE) followed by immunoblotting with
an HBx-specific monoclonal antibody (B-8/2/8) (37). Protein bands were visual-
ized using the enhanced chemiluminescence (ECL) system (Santa Cruz Biotech-
nology). pET-X-expressing X protein in Escherichia coli (rec-HBx) after isopro-
pyl--D-thiogalactopyranoside induction was used as a position marker for X
protein during immunoblotting (25).
(ii) RT-PCR amplification of HBx gene-specific transcript. Total hepatic RNA
from various mice was isolated using the TRIZOL reagent (GIBCO BRL). The
primer set designed for HBx included the following: sense, 5-CGGAATTCCA
TATGCTCCCCGCTGTGCCTTC-3; antisense, 5CGGAATTCGGATCCTT
ATTTGTGC CTACAGCCTCCTAA-3. DNase I (GIBCO BRL)-treated RNA
was reverse transcribed using Superscript RNase H reverse transcriptase (RT)
(GIBCO BRL) and gene-specific antisense primer as per the manufacturer’s
protocol. PCR amplification (35 cycles) of the RT product was performed using
high-fidelity Platinum Taq DNA polymerase (GIBCO BRL) with a cycling pro-
file of 94°C for 45 s, 62°C for 45 s (or 55°C for 45 s in the case of -actin primers;
Stratagene), 72°C for 1 min, and a final extension at 72°C for 10 min. A specific
amplified product of 270 bp of the HBx gene was visualized by ethidium bromide
staining on a 1.5% agarose gel. As a control, -actin mRNA was also amplified
by RT-PCR for each sample, and a product of 650 bp was obtained. Southern
hybridization was performed to further confirm the specificity of the RT-PCR
product using a 32P-labeled HBx DNA fragment as the probe.
Kinase assay. The ERK assay was performed following a published protocol
(9) with some changes. In brief, hepatocytes isolated from mouse livers were
lysed in a lysis buffer (20 mM Tris-HCl, pH 7.5, containing 150 mM NaCl, 1.0%
Triton X-100, 10% glycerol, 1 mM dithiothreitol, 1 mM NaF, 1 mM Na3VO4, 20
mM para-nitrophenyl phosphate, 50 mM -glycerol phosphate, 1 mM EGTA, 2
mM PMSF, 1.5 mM MgCl2, and 20 g each of aprotinin and leupeptin [Sigma]/
ml along with Complete protease inhibitor cocktail [Roche]). Protein concen-
tration in the lysates was measured by the Bradford assay. Assessment of ERK/
MAPK activity was carried out by in vitro phosphorylation of exogenous
substrate myelin basic protein (MBP) (GIBCO BRL). For each sample, 5 g of
protein lysate was used in a reaction containing 5 g of MBP in kinase buffer (20
mM Tris-HCl [pH 7.5], 40 mM MgCl2, 10 M ATP [Sigma]) and 2 Ci of
[-32P]ATP (Amersham Pharmacia Biotech) and incubated for 30 min at 30°C.
The reaction was stopped by the addition of Laemmli sample buffer and resolved
on SDS–15% PAGE. The upper half of the gel was used for Western analysis
with anti-ERK antibody (Santa Cruz Biotechnology) using the ECL detection
system. The lower half of the gel containing MBP protein was dried and exposed
to X-ray films. Coommassie blue (CB) staining was done with the dried blot to
check for equal amounts of MBP present in each reaction. The stained MBP
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bands were excised, and incorporated radioactivity was measured by liquid scin-
tillation counting for calculating fold activation.
Detection of phosphorylated ERK and JNK by immunoblotting. The level of
active forms of ERK (P-ERK) and c-Jun N-terminal MAPK (P-JNK) in the
hepatocyte cell lysates (5 g each) were examined separately by Western blotting
with anti-phospho-p44/42 MAPK antibody and Phospho Plus SAPK/JNK Anti-
body (Cell Signaling Technology), respectively. Respective blots were stripped
and reprobed with anti-ERK antibody and anti-JNK antibody.
Preparation of nuclear extracts and gel mobility shift assay. Nuclear extracts
from each liver lobe and HepG2 cells were prepared as described by Lassar et al.
(38). Corresponding cytosolic extracts obtained were used for immunoprecipi-
tation of the HBx protein by anti-HBx antibody. Electrophoretic mobility shift
assays (EMSA) were carried out essentially following a published protocol (11).
The synthetic oligonucleotides used as a probe or competitor DNA in this assay
consisted of double-stranded TRE sequence (Promega). Binding reactions with
36 g of liver nuclear extracts and 6 g of HepG2 cell extracts were carried out
for 60 min at 4°C followed by incubation for 5 min at 25°C using 10,000 cpm of
32P-labeled probe and 1 g of poly(dI  dC) (Sigma). Competition binding
experiments were performed with unlabeled oligonucleotide in excess. The re-
action mixture was resolved on a 4% nondenaturating polyacrylamide gel, dried,
and visualized by autoradiography or PhosphorImaging analysis. For antibody
(supershift) studies, 4 g of antiserum (Santa Cruz Biotechnology) to either
c-Jun or c-Fos was added after completion of the binding reaction and incubated
at 28°C for 20 min. Seventy micrograms of the same nuclear extracts were
subjected to Western blotting using specific antibody as described for the super-
shift assay and visualized by the ECL detection system.
RESULTS
Expression of HBx gene in mouse liver following F-viro-
some-mediated delivery. To test exogenous HBx gene expres-
sion in mouse liver, hepatocytes isolated 2 days after injection
of loaded virosomes were analyzed by Western blotting using
the monoclonal antibody B-8/2/8 (Fig. 1a). A band correspond-
ing to the 16.5-kDa protein (lane 4) similar in mobility to a
recombinant X protein (rec-HBx; lane 5) (25) was detected
only in mouse hepatocytes injected with the HBx gene, con-
firming both the expression and structural integrity of the HBx
protein in hepatocytes. Mock injection, vector-loaded viro-
somes, and free DNA (lanes 1 to 3) served as negative controls.
Total RNA was isolated from the same liver biopsies and
examined for HBx-specific mRNA through RT-PCR analysis
(Fig. 1b). As expected, amplified product of HBx-specific tran-
script was obtained (lane 4, upper and middle panels), while no
corresponding band was seen in any of the negative controls
(lanes 1 to 3). Equal loading of RNA and its integrity were
confirmed by RT-PCR analysis of -actin mRNA (Fig. 1b,
lower panel). In a separate experiment, the hepatocyte-specific
HBx gene delivery was confirmed by the absence of any de-
tectable level of protein or RNA in nonparenchymal cells and
other tissues, such as those from heart, lungs, kidneys, brain,
spleen, and skeletal muscle (data not shown). Absence of any
detectable protein or RT-PCR signal from administration of
free HBx DNA demonstrated the efficiency of this delivery
mode. Furthermore, the presence of the HBx protein in indi-
vidual hepatocytes was demonstrated by immunohistochemical
analysis with the fixed liver tissue sections (Fig. 1c). Immuno-
staining of liver sections from experimental mice (2 days
postinjection) using the monoclonal antibody B-8/2/8 showed
that as much as 50 to 70% of the hepatocytes were expressing
the HBx protein following introduction of 2 g of HBx DNA
entrapped in virosomes (panel 1). Importantly, HBx expression
was exclusive for the hepatocytes, in conformity with the cell-
specific nature of the virosomal delivery system in vivo. How-
ever, we found heterogeneity in terms of both distribution of
HBx-expressing hepatocytes and the relative level of HBx per
cell over the entire liver (data not shown). We anticipate that
such a phenomenon may be attributed to differential delivery
of the HBx gene by virosomes. Even more impressive was the
observation that livers receiving 5 g of the HBx plasmid
through virosomes showed a nearly complete transfection with
intense staining. No immunostaining was detected in the liver
sections from vector-injected control mice (panels 2 and 4).
This observation indicates that by augmenting the dose of
delivered HBx gene, both the number of hepatocytes getting
transfected and the abundance of the HBx protein per cell can
be increased. Overall, these results establish the virosome-
mediated delivery of the HBx gene specifically to the hepato-
cytes in vivo, as confirmed both by expression of the protein
and its transcript. Considering its sensitivity, only RT-PCR
analysis has been utilized throughout our experiments as a
clear reflection of HBx gene expression. It is noteworthy that
all the animals remained healthy and active during the entire
study.
Activation of ERKs by HBx in mouse hepatocytes. Following
successful expression of HBx in mouse hepatocytes, we next
evaluated its transactivation potential in activating mitogenic
signaling pathways in vivo. Hepatocyte lysates prepared from
HBx-, vector-, and insulin-injected mice were tested for the
phosphorylation of ERK1 and ERK2 (ERK1/2). As shown in
Fig. 2a (upper panel), HBx-expressing hepatocyte lysates (lane
3) showed a significant increase of P-ERK levels over the
controls (lanes 1 and 2), similar to that in insulin-induced cell
lysates (positive control, lane 4). Nonetheless, the extent of
expression of ERK1/2 was not altered significantly in any of the
samples (lower panel). Note that although the presence of both
ERK1/2 forms of MAPK were detected in all the samples
tested, the two distinguishable forms of the corresponding P-
ERKs were not readily apparent, perhaps owing to the comi-
gration after phosphorylation. In addition, the functional ac-
tivity of phosphorylated ERK proteins in these extracts was
defined by an in vitro kinase assay using MBP as a specific
substrate. In agreement with the elevated P-ERK activity, a
four- and fivefold elevation in MBP phosphorylation were ob-
served in lysates from HBx and insulin-injected animals, re-
spectively (Fig. 2b, upper panel, lanes 3 and 4, and Fig. 2c).
Equal protein loading in all blots was verified by Ponceau S red
staining (data not shown). Insulin, a well-known stimulator of
ERK in Ras-Raf-MAPK cascades (13), alluded to the involve-
ment of this pathway in HBx-induced ERK up-regulation in
vivo. These observations established the potential of the HBx
protein to stimulate the ERK cascade in vivo.
Dose-dependent activation of ERKs by HBx. We determined
the kinetics of ERK activation by HBx and determined the
optimum conditions under which functional analysis of HBx
could be done. Following injection of increasing amounts of
HBx DNA through virosomes, there was a dose-dependent
enhancement of both phosphorylation (Fig. 3a, upper panel)
and activity (Fig. 3b, upper panel, lanes 2 to 5) of ERK1/2. We
observed a fourfold increase in the level of MBP phosphory-
lation following injection of 1 g of HBx DNA (Fig. 3c). With
a further increase in the quantity of DNA, the MBP phosphor-
ylation level increased only moderately and reached a plateau
at 5 to 10 g. Steady-state levels of ERK1/2 remained unal-
tered in all DNA doses studied (Fig. 3a and b, lower panel).
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FIG. 1. Exogenous expression of HBx in mouse liver. (a) Immunodetection of HBx protein following virosome-mediated HBx gene delivery to
mouse liver. Hepatocyte lysates prepared from mouse livers were resolved by SDS-PAGE and visualized by Western blotting as described in
Materials and Methods. (b) Analysis of HBx transcript. Total RNA from a portion of the same liver samples was isolated and analyzed by RT-PCR.
The ethidium bromide staining of the PCR product is shown in the upper panel, and Southern hybridization of the same is shown in the middle
panel. Corresponding samples were also analyzed for -actin mRNA (lower panel). (c) Immunohistochemical analysis of HBx protein in fixed liver
tissues as a function of DNA dose. Two days postinjection, liver sections from mice injected with 2 g (panel 1) and 5 g (panel 3) of HBx
DNA-loaded virosomes were immunostained with an HBx-specific monoclonal antibody (B-8/2/8). Nuclei were visualized (blue color) by
counterstaining with hematoxylin. The immunoreactive cells appeared pink with Fast-Red dye. Panels 2 and 4 represent liver sections from mice
injected with 2 and 5 g of pSG5 vector DNA-loaded F-virosomes, respectively.
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RT-PCR analysis of the experimental cell extracts was positive
for the presence of HBx transgene (Fig. 3d, upper panel).
Considering this result, further functional studies of HBx were
carried out at the submaximal plasmid quantity of 2 g.
PD98059 selectively blocks both the phosphorylation and
activity of the HBx-induced ERKs. To ensure whether HBx
specifically activates ERK in vivo, we utilized the specific in-
hibitor of MEK, the kinase that activates ERK1/2 through
phosphorylation (1). The effect of this inhibitor on the ERK
activation profile in insulin-injected animals was taken as a
positive control. In a notable contrast with the case for un-
treated animals, both HBx-mediated activation of MAPK (P-
ERK level) (Fig. 4a) and its activity (fold increase in MBP
phosphorylation) (Fig. 4b and c) were effectively abrogated
(	66% inhibition) by this MEK inhibitor (Fig. 4b, upper panel,
compare lanes 3 and 4). The similar inhibition (	66% inhibi-
tion) of the insulin-mediated ERK activation pathway further
confirmed the mode of action of PD98059 in vivo (Fig. 4b,
upper panel, compare lanes 5 and 6). All liver samples injected
with HBx DNA that were tested for MAPK activity exhibited
HBx gene expression (Fig. 4d, upper panel, lanes 2 and 3). No
significant differences in ERK1/2 protein levels were noted as
FIG. 2. HBx-mediated activation of ERK in hepatocytes. (a) De-
termination of P-ERK levels. Hepatocyte lysates were subjected to
SDS-PAGE followed by Western blotting using anti-phospho-p44/42
MAPK antibody as described in the text (upper panel). The same blot
was stripped and reprobed with anti-ERK antibody (lower panel). (b)
Assessment of functional activity of activated ERKs. The lysates used
above were assayed for kinase reactions and resolved by SDS-PAGE.
The lower half of the gel was autoradiographed (upper panel), fol-
lowed by CB staining (middle panel), and the upper half was subjected
to Western blotting with ERK antibody (lower panel). (c) Fold acti-
vation of MBP phosphorylation. The MBP bands were excised, and
radioactivity was measured by liquid scintillation counting.
FIG. 3. Dose-dependent activation of ERK by HBx. (a) Equal
amounts of hepatocyte lysates were taken for the analysis of P-ERK
levels (upper panel) and total ERK levels (lower panel) as described in
the legend for Fig. 2. (b) The same lysates were subjected to kinase
reactions for evaluation of 32P-MBP profile (upper panel), CB staining
of MBP (middle panel) and total ERK levels (lower panel). (c) Fold
activation of MBP phosphorylation. (d) RT-PCR amplification of HBx
(upper panel) and -actin transcripts (lower panel) present in total
RNA from each liver specimen was carried out as described in the text.
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a result of the introduction of the MEK inhibitor (Fig. 4a and
b, lower panels). Such inhibition by PD98059 provides phar-
macological evidence that HBx specifically stimulates ERKs in
vivo.
Enhanced and sustained activation of ERKs in the HBx-
expressing hepatocytes. Activation of the ERK cascade has
been well implicated in cell proliferation and differentiation.
However, constitutive activation of this pathway has been re-
FIG. 4. Effect of PD98059 on ERK activation in vivo. (a) PD98059
inhibits both HBx-and insulin-induced ERK phosphorylation.
PD98059 was administered i.v. to two groups of mice, one injected with
virosomal HBx DNA and the other with insulin prior to sacrifice, as
mentioned in the text. Hepatocyte lysates were evaluated for both
ERK1/2 phosphorylation (upper panel) and the total ERK level (lower
panel) by immunoblotting. (b) Inhibition of MBP phosphorylation by
PD98059 in the lysates from HBx DNA and insulin-injected mouse
liver. Kinase reactions were conducted with the corresponding lysates
(upper panel). Equal levels of MBP (CB staining) in all reactions are
shown in the middle panel. The total ERK level was monitored, as
shown in the middle panel, essentially by SDS-PAGE analysis and
Western blotting, as described in the text. (c) Fold activation of MBP
phosphorylation. (d) Evaluation of the presence of HBx transcripts
(upper panel) and the -actin mRNA profile (lower panel) in the liver
samples injected with HBx DNA.  and  represent the presence and
absence of PD98059, respectively.
FIG. 5. Kinetics of ERK activation by HBx. (a) Extent of phos-
phorylation of ERKs (upper panel) and total ERK level (lower panel)
in the hepatocyte lysates made from mice livers at different time points
following a single injection of either virosomal HBx DNA or pSG5
vector. d, days. (b) MBP phosphorylation levels (upper panel), MBP
levels (middle panel), and total ERK status (lower panel) in the same
lysates. (c) Fold activation of MBP phosphorylation. (d) Tissue sam-
ples taken from all the time points were evaluated for the presence of
HBx (upper panel) and -actin mRNA transcripts (lower panel). (e)
Western blot analysis of HBx protein following immunoprecipitation
with anti-HBx monoclonal antibody (B-8/2/8) from liver cytosolic ex-
tracts. V, cell lysates from mice sacrificed 30 days after injection of the
virosomal pSG5 vector.
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ported as one of the key reasons for the induction of a trans-
formed phenotype by many oncogenes (34, 44, 45). Therefore,
to explore the possibility of a similar aberrant activation sce-
nario in vivo induced by HBx, hepatocyte lysates taken at
progressive time points after the introduction of the HBx gene
were examined for ERK activation using both the anti-phos-
pho-ERK antibody assay (Fig. 5a) and the in vitro MBP kinase
assay (Fig. 5b). Both the assays indicated significant upregula-
tion of P-ERK and 32P-MBP levels (three- to fivefold over that
of the negative controls [Fig. 5b, upper panel, lanes 1 to 10, and
Fig. 5c]). Such activation was apparent as early as 0.25 day
(lane 2) and peaked at 0.5 day (lane 3), and strikingly, it
remained elevated (up to threefold over the control) up to 30
days (the last time point studied) (lanes 4 to 10). In contrast, no
significant increase in the steady-state levels of total ERK1/2
was evident during such an extended period of HBx expression
(Fig. 5a and b, lower panels). The RT-PCR profile and West-
ern blot analysis from liver tissues showed a continued expres-
sion of the HBx gene till 30 days (Fig. 5d, upper panel, and e,
lanes, 2 to 10). Therefore, expression of HBx in vivo leads to
the activation of the ERK pathway, as observed in the case of
oncogene-mediated sustained ERK activation (45).
Persistent activation of AP-1 in HBx-expressing hepato-
cytes. Activation of the MAPK cascade leads to the induction
of AP-1 transcription factors and is generally implicated in
proliferation and tumorigenesis (3, 26, 62, 67). Since in this
study, HBx persistently activated ERKs, we next tested if the
AP-1 binding activity was stimulated and maintained by HBx
amidst the natural hepatocyte environment. To begin with, an
EMSA was carried out using equal amounts of nuclear extracts
FIG. 6. HBx mediates upregulation of c-Jun-c-Fos levels and sus-
tained activation of AP-1 binding activity. (a) The EMSA was per-
formed as described in the text with the nuclear extracts prepared from
a portion of the same livers mentioned in the legend for Fig. 5.  and
 indicate the absence and presence, respectively, of a 50-fold molar
excess of cold competitor during the DNA-protein interaction. () S
and () S represent the HepG2 nuclear extracts without and with
serum induction, respectively. PD stands for the PD98059 inhibitor. d,
days. (b) Composition of the AP-1 binding complex was judged by a
supershift assay as mentioned in the text.  and  represent the
supershifted AP-1 complex in the presence of c-Fos and c-Jun anti-
bodies, respectively. IgG indicates the normal rabbit serum taken as
negative control. (c) Induction of the c-Jun protein was analyzed by
Western blotting in the same nuclear extracts (used for EMSA) with
c-Jun antibody. V, cell extracts from vector-injected mice. (d) Upregu-
lation of the c-Fos protein was analyzed independently in the same
nuclear extracts with c-Fos antibody. () S and () S, HepG2 extracts
as used in panel a.
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and the end-labeled AP-1 probe (Fig. 6a). HBx protein expres-
sion resulted in a sharp increase in AP-1 binding activity as
early as 0.25 day following HBx gene administration, which
reached the maximum at 0.5 day and remained elevated for up
to 30 days (Fig. 6a, lanes 2 to 9). It is worth mentioning that
liver samples used here are the same that were used for the
ERK assay as described in the legends for Fig. 4 and 5. An
excess of unlabeled AP-1 sequence effectively competed the
protein-DNA complex (lanes 11 and 12), confirming the spec-
ificity of AP-1 binding. Furthermore, inhibition of AP-1 bind-
ing activity by PD98059 revealed the role of ERK in HBx-
induced AP-1 activation (lane 10). Mice injected with vector
DNA showed a basal level of DNA binding activity and served
as a negative control (lane 1). Nuclear extracts were prepared
from serum-starved and serum-stimulated HepG2 cells and
used as negative and positive controls, respectively, as a mea-
sure of induction of AP-1 binding activity (lanes 13 and 14). To
assess the composition of AP-1 binding complex, a supershift
assay was also performed. Addition to nuclear extracts of an-
tibody to c-Jun and c-Fos but not IgG resulted in supershifted
complexes. Collectively, these results indicate that HBx expres-
sion also leads to a sustained increase in AP-1 binding activity
comprised of the c-Jun and c-Fos heterodimer (Fig. 6b). To
account for the persistent appearance of c-Jun and c-Fos pro-
teins in the AP-1 complex, Western blots of the same nuclear
extracts were performed using antibodies to c-Jun and c-Fos.
Figure 6c and d show a significant increase in both c-Jun and
c-Fos levels over that of the vector, suggesting that the increase
of AP-1 binding activity occurs by an increase in de novo
synthesis of c-Jun and c-Fos proteins.
Induction of c-Jun levels: a consequence of prolonged acti-
vation of c-Jun N-terminal kinases (JNKs) by HBx. Recent
studies have provided evidence that JNKs are activated inde-
pendently of ERKs and that following mitogenic stimuli, c-Jun
acts as a downstream target of JNK activation (17, 46, 47, 49,
52, 58). Therefore, to determine whether JNK has any role in
mediating the effect of HBx expression, we critically examined
the levels of the phosphorylated form of JNKs (P-JNKs) and
vis-a`-vis the total JNKs in the HBx-transfected hepatocyte ex-
tracts (Fig. 7). A sharp increase in the phospho-JNK-specific
bands, similar in pattern to HBx-induced ERK activation (Fig.
5), was observed in the hepatocyte lysates positive for HBx
expression for a period from 0.25 to 30 days (Fig. 7, lanes 4 to
11). As observed in the case of ERKs, the total level of JNKs
in all the time points tested remained unaltered in the presence
of HBx transgene products (Fig. 7, lower panel).
Long-term HBx protein expression: an outcome of integra-
tion of DNA in the chromosomes of hepatocytes. To account
for the sustained signal observed, we examined for the pres-
ence of HBx protein in the hepatocytes of liver sections 30 days
postinjection by immunohistochemistry (Fig. 8a). As is evident
from panel 1, nearly 70% of the hepatocytes sustained HBx
gene expression. In an attempt to corroborate this observation,
we carried out a systematic analysis on the status of the deliv-
ered HBx DNA in the host genome. Southern analysis (Fig.
8b) revealed the integration of the HBx gene in the chromo-
somal DNA from 3 days onward (till 30 days, the last time
point taken).
DISCUSSION
In the present study, we expressed HBx in its physiological
environment of hepatocytes in whole animal and analyzed its
role as a transactivator in influencing mitogenic signaling path-
ways. Importantly, we demonstrate that HBx has the potential
to activate MAPKs and AP-1 in a sustained manner resembling
the mechanism of action of oncogenic stimulus.
HBx is implicated in HBV-mediated hepatocarcinogenesis,
and its oncogenic potential is demonstrated with the CD1
strain of mouse (29) and cultured cell lines FMH202, AML12,
and REV2 (2). Although the precise role of HBx in HCC
remains unclear, HBx transactivation function in modulation
of the signal transduction pathways could be envisaged as one
of the possible mechanisms for carcinogenesis (4). The rele-
vance of HBx-induced signaling cascades in cellular transfor-
mation could not be assessed by the available systems, as they
fail to reproduce the normal hepatocyte environment due to
constraints imposed by an altered genetic background. For
example, the mouse CD1 strain is characterized by a high
incidence of spontaneous cancer (22), while the immortalized
cell lines have the insertion of certain transgenes, such as those
for the epidermal growth factor receptor in AML12 (50), SV40
large T in FMH202 (21), and E1A in REV2 (20), that alter the
normal physiological functions of the hepatocyte. Neverthe-
less, the ability of HBx to activate MAPK pathways is shown in
transformed cell lines (9). However, recently Tarn et al. dem-
onstrated that HBx-dependent induction of signaling cascades
and the expression of their downstream immediate-early gene
products c-Fos and ATF3 differed in transformed and non-
transformed hepatic cell lines, in terms of both magnitude and
duration (60). Furthermore, because of inherent problems,
such as short life span, dedifferentiation, and difficulty in
transfection, primary hepatocytes are not suitable for studying
HBx-transactivating potential in oncogenesis (2, 14, 21). Such
studies therefore implicate the prerequisite of the normal,
nontransformed, and differentiated environment of hepato-
cytes and foster the importance of in vivo studies for functional
analysis of HBx. However, none of the putative roles of HBx in
the signaling cascades has been proven using animals in vivo.
For these reasons it is especially important to study the acute
effect of HBx expression in intact livers.
FIG. 7. Induction of JNKs by HBx. Equal amount (5 g) of the
same hepatocyte cell extracts mentioned in the legend for Fig. 5 were
subjected to Western blotting, and bands corresponding to activated
JNKs (P-JNK, upper panel) and total JNKs (JNK1/2, lower panel)
were detected. () UV and () UV represent total cell extracts from
unirradiated and irradiated 293 cells as the negative and positive con-
trol, respectively. V, cell extracts from mice sacrificed after 30 days of
virosomal vector DNA injection; d, days.
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HBx-expressing hepatocytes displayed an activation of
ERK1/2 that was fourfold that of the negative controls and
validated the in vitro observations of ERK activation by HBx
(9) but contradicted the findings of Bergametti et al. in CCL-13
cell lines (12). The specificity of stimulation of ERK by HBx
was further confirmed by the effect of a cytostatic drug,
PD98059, that is a specific and efficient inhibitor for MEK (1),
also suggesting that HBx-induced ERK activation requires
MEK. ERK activation was induced rapidly within hours after
the introduction of HBx and was prolonged over a period of 30
days. This sustained activation of ERK1/2 is to be contrasted
with the transient activation seen in response to various growth
factors where activity is maximal in 5 min and subsides rapidly
within 30 to 60 min (31). The constitutive activation of ERKs
by HBx appears to be similar to what has been observed with
many oncogenes (15, 44, 45, 65). Previous studies show that
transformation by oncogene products like Ras, Src, and Abl
accompanies the constitutive activation of MAPK signaling
pathways (44, 45, 65). Aberrant and inappropriate activation of
MAPK has also been shown to be the hallmark of many human
tumors, including HCC (23, 24, 42, 57). Prolonged activation of
MAPKs by HBx thus implicates its possible oncogenic poten-
tial. Importantly, our observations clearly imply that such sus-
tained ERK activation precedes HCC rather being its conse-
quence.
We demonstrate that the prolonged activation of the ERK
activity by HBx expression is also accompanied by the activa-
tion of JNKs, which constitute another important member of
the MAPK family primarily implicated in stress response. The
activation of JNKs in the intact liver by HBx is in agreement
with the similar observations made by Benn et al. with cultured
hepatocytes (11). ERKs and JNKs are associated with diver-
gent biological responses. While ERKs are linked to growth
and differentiation, the JNK pathway induces apoptosis (17).
Our observations that the ERK and JNK pathways are simul-
taneously activated by HBx are, however, not unusual in the
context of numerous studies which demonstrate that activation
of both the ERK and JNK signaling pathways is required to
trigger a full spectrum of phenotypic traits associated with
cellular transformation and oncogenesis (17, 63). In addition, it
is known that the JNK-dependent apoptotic signaling pathway
can be blocked by activation of survival signaling pathways,
such as those of ERK, NF-
B, and Akt/PKB (17). A recent
study paradoxically shows that JNKs act synergistically with
ERKs to enhance a proliferative effect by phosphorylating
c-Jun and protecting cells from apoptosis (64). Therefore, JNK
pathway functions within the overall context of the state of
FIG. 8. Persistence of the HBx gene and its protein 30 days after
injection of DNA-loaded virosomes. (a) Immunohistochemical detec-
tion of the HBx protein was carried out as described in the legend for
Fig. 1c. Panels 1 and 2 represent liver sections from mice 30 days after
of injection with 2 g of HBx and pSG5 DNA-loaded virosomes,
respectively. (b) Integration status of the HBx gene in mouse livers at
different time points. Total genomic DNA was digested with
KpnI/HindIII followed by Southern hybridization with the HBx DNA
fragment as a probe. Lane 1 represents the 4.5-kb XbaI-linearized HBx
plasmid (HBx gene containing the pSG5 vector). V, digested genomic
DNA from mice sacrificed 30 days after injection of the virosomal
pSG5 vector.
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activation of other signaling pathways. In the light of this evi-
dence we propose that HBx-induced JNK activation acts in
accord with ERK activation, having a coherent effect on cell
proliferation.
Activated ERKs and JNKs mediate their effects by translo-
cating into the nucleus, phosphorylating various transcription
factors, and thus reprogramming gene expression (3, 26, 17).
Members of the AP-1 family of transcription factors are sub-
strates for ERK/JNK activities and are the primary mediators
of mitogenic stimulation (3, 26, 62, 67). Our results evidenced
increased binding activity of AP-1 that precisely followed the
pattern of ERK/JNK activation. Previous studies show a role of
AP-1 comprised of the c-Jun–c-Fos heterodimer in cell prolif-
eration (35, 62, 67). Recent studies have documented that Jun
can promote cyclin gene expression and cell cycle progression
(8). Note that in HepG2 cells in culture, inhibitory AP-1 com-
plexes composed of Jun-Fra heterodimers, induced by BHQ,
antagonize the transcriptional effects of the tumor promoter
tetradecanoyl phorbol acetate, which are mediated by Jun-Fos
heterodimers (66). Therefore, an increase in c-Jun and c-Fos
heterodimers comprising the AP-1 complex suggests that most
of the effect of HBx is in inducing stimulatory AP-1 complexes.
However, our results are in contrast to the in vitro results
found by Benn et al., where the Jun-Fos heterodimer was
replaced by a Jun homodimer after 24 h (11). On the other
hand, the findings of Kekule´ et al. (27) that both Jun and Fos
are needed to mediate AP-1 activation by HBx are authenti-
cated by our in vivo results. Our observations on increased
levels of c-Fos protein in HBx-expressing liver cells support the
findings of Avantaggiati et al. with AML12 cells in vitro (5),
although they are in discordance with the transient c-Fos levels
observed by Benn et al. in Chang and HepG2 cell lines (11).
The discrepancies observed with cultured cells prove the lim-
ited value of in vitro systems for such functional analysis and
highlight the importance of our in vivo findings. Moreover, the
increased c-Jun and c-Fos levels observed in our study might
have relevance for hepatocyte transformation in the light of a
recent report on the high endogenous levels of AP-1 in onco-
genic activity compared to that needed for normal growth (62).
Studies by Ito et al. on elevated MAPK activity and c-Fos levels
in human HCC lend further support to our speculation (24).
Notably, we observed a transient decline in both Jun and Fos
levels during days 1 to 6, followed by another burst of Jun and
Fos induction. It is anticipated that during the first phase of
enhanced AP-1 activity, a distinct gene expression program is
activated which subsequently stabilizes the enhanced AP-1 ac-
tivity and possibly leads to cellular transformation.
Although our study suggests a potential role of HBx-induced
signaling cascades in carcinogenesis, it does not preclude the
involvement of additional mechanisms in such a process. It
might be speculated that HBx behaves as a weak oncogene that
alone is not sufficient but requires other cooperating oncogenic
alterations, such as inactivation of p53 or overexpression of
c-myc or cyclin D1, for malignant transformation. While HBV-
associated HCC is a multistep process, it is likely that HBx
alone may not lead to tumor formation but rather may con-
tribute by deregulating cellular processes that eventually lead
to liver cancer. Alternatively, the X protein might play a deci-
sive role in hepatocarcinogenesis (till the precancerous phase
only) but may not be necessary to maintain the tumor pheno-
type (16, 28, 56). In summary, we demonstrate that introduc-
tion of HBx in the adult mouse liver rapidly activates ERKs
and JNKs and leads to an increase in AP-1 activity through the
induction of the c-Fos and c-Jun proteins. The effect appears to
be sustained, most likely because of the integration of the HBx
gene into the host cell chromosome and its continued expres-
sion. The importance of our study lies in the fact that it de-
scribes the early cellular signaling events related to HBx-me-
diated carcinogenesis. The present report thus establishes for
the first time a murine model for studying the molecular basis
of HBV pathogenesis that can be used for further investiga-
tions on multistep process leading to HCC.
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